Angiotensin II-preconditioning (APC) has been shown to reproduce the cardioprotective effects of ischaemic preconditioning (IPC), however, the molecular mechanisms mediating the effects of APC remain unknown. In this study, Langendorff-perfused rat hearts were subjected to IPC, APC or both (IPC/APC) followed by ischaemiareperfusion (IR), to determine translocation of PKCε, PKCδ, Akt, Erk1/2, JNK, p38
regulation of apoptotic proteins (Bax, Bcl-2, and caspase 3) 12, 13 to promote cell survival and tissue integrity.
Protein kinase C (PKC) appears to be a central player mediating cardioprotective effects of IPC and APC because inhibition of this kinase abolishes the beneficial effects of both preconditioning.
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By contrast, stimulation of PKC activity with phorbol esters 17, 18 replicate cardioprotective signals against IR injury. Indeed, GPCRs agonists including Ang II, 1 appear to mimic IPC through PKC. From 11 known PKC isoforms, two seem to play key roles in cardioprotection.
These isoforms, PKCɛ and PKCδ, act on effectors such as the mito-K ATP channels, mitogen-activated protein kinases (MAPKs), and the mitochondrial permeability transition pore (mPTP). 19 PKC isoforms are activated by 3-phosphoinositide-dependent protein kinase-1 (PDK1)-dependent phosphorylation 20 and subsequently translocate to subcellular organelles during the preconditioning or at the beginning of reperfusion. 21 The process is isoform specific, and through a cytoskeleton mediated process, results in phosphorylation and activation of the effectors of preconditioning. 16 For this reason, the translocation of PKC is considered a hallmark for PKC activation and has been used as an indicator of activation following preconditioning stimuli. 22 PKCɛ has been reported to exert cardioprotection by opening the mitoK ATP channel and inhibiting the mPTP, 23 while PKCδ is associated with increased superoxide anion generation, loss of mitochondrial function, as well as the enhanced release of cytochrome c and downstream proapoptotic factors. 24, 25 The design of isoform-specific peptides that inhibit PKCɛ translocation has confirmed the requirement of this step in preconditioning. 26 By contrast, peptides that promote translocation of PKCɛ have been shown to induce cardioprotection against IRmediated damage. 27 Accumulating evidence shows that ROS production from Ang II type 1 receptor (AT1-R) stimulation results from activation of NADPH oxidase. 10 Indeed, studies have demonstrated that Ang II increases the activity of subunits gp91phox, gp22phox and p47phox. 6, 28, 29 Similar to IPC, Ang II also stimulates mitochondrial ROS production, which may further stimulate NADPH oxidase expression and activity. 30, 31 Besides, MAPKs, 10, 29, 32 such as Erk1/2, JNK and p38 MAPK are main targets of ROS signalling and AT1-R activation, 9 but their role in IPC and APC is still not fully understood. Indeed, conflicting data 33 exists on the role of JNK and p38 MAPK in cardioprotection. These kinases are part of the family of stress-activated MAPKs implicated in cell death. 19, 34 However, they may also promote cardioprotection depending on the dynamics of activation and their interaction with protective pathways. 33 , Therefore, there is a need to evaluate the role of stress-activated MAPKs and the prosurvival kinase pathway 35 (PI3K, Akt and Erk1/2) in APC.
Previous work from our laboratory, 7 demonstrated that APC enhances the post-ischaemic recovery of the heart, reduces infarct size and LDH release, and improves mitochondrial function. However, treatment with chelerythrine during preconditioning did not affect the post-ischaemic recovery of cardiac function. These findings suggested that the post-ischaemic cardiac recovery in chelerythrine-treated hearts relies on PKC-independent pathways or, PKC-dependent signalling pathways activated at reperfusion. However, the lack of data on PKC-dependent signalling pathways in APC in the presence or absence of chelerythrine precluded the evaluation of these possibilities.
F I G U R E 1 Schematic representation of the perfusion protocols. See "Methods" for details
In this work, we evaluated further the mechanisms involved in APC, IPC, and their combination, to clarify the role of PKC and its downstream signalling targets in these processes. Protein kinases can be affected by different types of post-translational modifications (phosphorylation, nitrosylation, SUMOylation, etc.) that do not necessarily result in kinase activation. 19 We chose to evaluate the translocation of protein kinases to the mitochondria because this process is an indicator of PKC activation during IPC. 22 Thus, the protein levels of PKCɛ, PKCδ, Erk1/2, Akt, JNK, p38 MAPK and GSK-3β, were determined in mitochondria to assess the APC-and IPC-induced translocation to these organelles. The role of PKC and AT1-R in APC and IPC/ APC was evaluated by using chelerythrine and losartan, respectively.
Also, the rate of mitochondrial swelling was used to determine the status of mPTP. Our results demonstrate that both APC and IPC/APC increase the AT1-R-dependent translocation of PKCɛ to mitochondria with no effect on PKCδ. A high PKCɛ/PKCδ ratio was associated with increased translocation of Erk1/2, Akt, and JNK to mitochondria and inhibition of mPTP. Inhibition of PKC with chelerythrine, however, blocked the signalling cascade but preserved the post-ischaemic cardiac recovery possibly by reducing the contracture-induced damage at reperfusion and increasing PKCδ expression. As depicted in Figure 2A , LVDP was stimulated by APC compared with controls (90% at 60 minutes, P <.001). A similar increase in this parameter was observed with IPC (data not shown). Figure 2B illustrates that IPC/APC markedly increased LVDP (2.8-fold at 60 minutes, P <.001)
| RESULTS

| Cardiac function in APC and IPC/APC hearts: effects of chelerythrine and losartan
over control values. Chelerythrine did not affect the increase of LVDP induced by APC or IPC/APC, but enhanced it in the control group (2.47-fold, P <.05, Figure 2A inset). By contrast, losartan significantly decreased LVDP by 82% (P <.05) in APC and 51% (P <.01) in IPC/APC when compared with their respective controls at 60 minutes. These results agree with a previous study from our laboratory 7 and support the view that cardioprotection by APC is an AT1-R-dependent event that is chelerythrine-insensitive under our experimental conditions.
| Effect of chelerythrine and losartan on ischaemic contracture and LDH release from hearts in both APC and IPC/APC groups
In control animals, 5 μmol/L chelerythrine administered prior to global ischaemia reduced 22% (P <.05) the ischaemic contracture (from 19 ± 2 to 15 ± 1 mmHg, n = 4) and 68% (P <.01) LDH activity in ventricular effluents at the start of reperfusion (from 100 ± 15 to 32 ± 8 units × 10 3 /mL x g heart weight, n = 4). In APC and IPC/APC hearts ( Figure 3A) , the drug also inhibited the ischaemic contracture by 55% (P <.001) in APC and 43% (P <.001) in the IPC/APC group.
Similarly, LDH release from perfused hearts treated with chelerythrine decreased 48% (P <.05) in APC and 37% (P <.01) in IPC/APC ( Figure 3B ). By contrast, losartan reduced ischaemic contracture by 27% (NS, P = .08) and 43% (P <.001) in APC and IPC/APC, respectively ( Figure 3A ). LDH release ( Figure 3B ) was also reduced by losartan 55% (P <.05) in APC and 28% (NS, P = .07) in IPC/APC. The data are consistent with reduced myocardial calcium during global Figure 5 shows the effect of chelerythrine when added during the preconditioning protocols or at reperfusion, on infarct size measured by the triphenyltetrazolium chloride (TTC) staining. Infarct size was reduced 61% and 67% by APC (P <.001) and IPC/APC (P <.001), respectively. In the presence of chelerythrine, however, the effect of APC was inhibited 59% and 72% (P <.05 for both) at preconditioning and reperfusion, respectively. Similar inhibitory effects of chelerythrine were observed on the reduction of infarct size induced by IPC/APC. These observations indicate that cardioprotection by APC and IPC/APC is mediated through PKC-dependent signalling pathways. Significant increases in mitochondrial Erk1/2 ( Figure 6E ) and Akt ( Figure 6G ) with IPC, APC and IPC/APC were observed (from 1.6 to 6.9-fold, P <.05 for each) compared with controls. However, in these studies chelerythrine was less effective in preventing the enhanced protein levels. Indeed, Akt protein was inhibited 49% (P <.01) by the drug in APC and 29% in IPC/APC although this value did not reach statistical significance. Significant inhibition by chelerythrine was also observed with Erk1/2 protein in APC (42%, P <.05) and the combined IPC/APC treatment (52%, P <.05).
| Effect of chelerythrine on infarct size determinations in APC and IPC/APC hearts
At variance with PKCɛ, Erk1/2 and Akt proteins, the effects of treatments on PKCδ ( Figure 6D ), JNK ( Figure 6F ), and p38 ( Figure 6H) were noticeably smaller. With the exception of JNK, which increased about 2-fold in mitochondrial fractions with IPC, APC, and IPC/ APC (P <.05 for all), mitochondrial PKCδ and p38 were unaffected by treatments. Only APC increased p38 protein levels (67%, P <.01).
Chelerythrine treatment inhibited JNK protein in mitochondria by APC (72%, P <.01), and IPC/APC (62%, P <.01) and abolished p38 protein levels in APC (P <.01). GSK-3β was not significantly affected (data not shown) by IPC, APC or their combination. These studies demonstrate that translocation to the mitochondria of PKCɛ, Erk1/2 and Akt (which occurs upon their activation) is involved in the cardioprotection induced by both preconditionings. in mitochondrial fractions. PKCɛ decreased 70% (P <.001) and 76% (P <.05) by losartan in APC and IPC/APC, respectively, while Erk1/2 was reduced 46% (P <.05) and 55% (P <.01), respectively. Similarly, Akt decreased by losartan 60% (P <.05) and 74% (P <.05) in APC and IPC/APC, respectively. PKCδ protein levels ( Figure 7D ) were not significantly affected by losartan although there was a tendency of the drug to inhibit protein levels in APC. JNK ( Figure 7F ) protein in APC and IPC/APC, however, were reduced 77% (P <.01) and 100% (P <.05)
| Effect of losartan on
by losartan, respectively. Likewise, the enhancement of p38 protein levels by APC ( Figure 7H ) was inhibited 89% (P <.01) by losartan. The drug also depressed p38 protein levels in IPC/APC (P <.01). These findings indicate that the increase of PKCɛ, Erk1/2, and Akt in mitochondria by APC and IPC/APC requires AT1-Rs.
| DISCUSSION
In this work, we evaluated the signalling mechanisms involved in APC to define the role of PKC-dependent signalling pathways in chelerythrine-and losartan-treated hearts. We demonstrated that mitochondrial levels of PKCɛ, but not PKCδ, markedly increased by APC, IPC and their combination. These findings suggest that activation and translocation of PKCɛ to the mitochondria is part of the mechanism by which these preconditionings mediate cardioprotection. Indeed, the translocation of PKCɛ to mitochondria was abolished by chelerythrine, a drug that inhibits the activity of all PKC isoforms by interacting with its catalytic domain. 14 The increased mitochondrial PKCɛ levels were associated with chelerythrine-sensitive Erk1/2 and Akt translocation, supporting an important role of the prosurvival kinase pathway in the cardioprotective effects of IPC, APC, and IPC/APC. The important role of the PKCɛ-dependent signalling in cardioprotection is evidenced by the fact that chelerythrine abrogated the reduction of infarct size by the APC or IPC/APC when added either at preconditioning or reperfusion. These findings also indicate that the reperfusion phase is required for preconditioning-induced cardioprotection as previously reported. 35 Altogether, these studies are consistent with a central role of PKCɛ in IPC and pharmacological preconditioning.
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F I G U R E 5 Effect of chelerythrine on infarct size in APC and IPC/APC treated rat hearts. Infarct size is expressed in percent of total area (whole heart). The values are shown as means ± SEM of six experiments per group. *P <.05, **P <.01, ***P <.001 vs Control; Indeed, studies in PKCδ knockout mice demonstrate increased injury after IPC. 44 Also, beneficial effects of PKCδ on cardioprotection have also been found in adult rats exposed to an intermittent hypoxia 47,48 and sevoflurane-induced preconditioning. 49 Preconditioning by chronic hypoxia, however, appears to depend on PKCɛ activity. 50 Therefore, the role of PKCɛ or PKCδ in cardioprotection is likely dependent on the preconditioning stimulus and the experimental conditions used. To our knowledge, this is the first study demonstrating that the cardioprotective effect of APC in chelerythrine-treated hearts is associated with reduced PKCɛ/PKCδ ratio in the mitochondria. Of note, chelerythrine also improved the post-ischaemic recovery (LVDP) of control hearts, suggesting that the improvement of cardiac function by the drug is independent of preconditioning. As mentioned above, the enhancement of cardiac recovery by chelerythrine could involve a reduction of contracture-induced tissue damage. However, it is likely that activation of PKCδ also contributes to the post-ischaemic cardiac recovery by the drug. This kinase can be phosphorylated on treonine505 in a chelerythrine-insensitive manner. 52 Moreover, PKCδ activity has also been related to alterations of Ca 2+ influx via Na , reperfusion damage, and LDH release, while as reperfusion injury proceeds, its effect on PKCɛ-dependent signalling and mPTP, reduce myocardial integrity and cell survival, and
increases infarct size. It should be noted that although chelerythrine prevented the reduction of infarct size by preconditioning, it promoted the post-ischaemic cardiac recovery (LVDP). These findings suggest a compensatory increase in myocardial contractility when tissue damage develops. We can only speculate that this compensation to sustain cardiac function, is due at least in part, to a PKCδ-mediated, enhanced contractility, as previously mentioned. By contrast with chelerythrine, losartan diminished the PKCɛ-dependent signalling, the ischaemic contracture, LDH release and the post-ischaemic cardiac recovery.
These findings agree with the role that PKC and intracellular Ca 2+ play in the reported inotropic effect of Ang II in cardiac tissue. 56 Accumulating data suggest that Akt is the upstream signalling of PKCɛ activation in IPC. 8 This fact is consistent with the relative Akt insensitivity to chelerythrine observed in this study. Indeed, the inhibitor partially reduced the enhancement of Akt by APC (49%) and IPC/ APC (29%). These results indicate that while Akt activation mediates cardioprotective effects through PKC in IPC, both PKC-dependent and PKC-independent mechanisms are involved in APC. Our findings are consistent with previous studies on the PKC-independent activation of Akt during ischaemia and PKC-dependent activation of Akt at reperfusion through GPCR sensitization as found for the adenosine receptor (A 2b AR). 8, 44 In contrast, Erk1/2 was markedly inhibited by chelerythrine in both APC and IPC/APC, suggesting that its activation is PKC-dependent. The latter possibly involves the Raf-MEK1/2 pathway at reperfusion. 35 Our results also show losartan-sensitive, upregulation of PKCɛ, Erk1/2, and Akt in APC and IPC/APC, indicating their involvement in AT1-R signalling pathways. 9 Another kinase that appears to be affected by APC and IPC/APC in a chelerythrine-and losartan-sensitive manner is JNK. Both chelerythrine and losartan decreased translocation of JNK to mitochondria and prevented the inhibition of the PTP by preconditioning. These findings suggest a role for JNK in the PKCɛ-dependent signalling mechanisms of APC and IPC/APC. Indeed, we have previously reported that inhibition of JNK with SU3327 causes mitochondrial dysfunction and aggravates the recovery of the heart after IR injury. 34 However, the stress-mediated activation of JNK in the heart is complex and depends on the spatial-temporal localisation and isoform activated. 8, 33 JNK promotes reactivation of Akt, and interacts with the apoptosome, delaying the activation of caspase 9. 57, 58 Whether its actions on the mitochondria, Akt or the apoptosome are involved in the post-ischaemic recovery observed in the present study remains to be determined.
Two additional kinases that are involved in preconditioning are p38
and GSK-3β. In this study, mitochondrial p38 was increased by APC in a chelerythrine and losartan-sensitive manner. In IPC/APC, this effect was not observed although losartan significantly (56%, P <.01) reduced p38 levels in IPC/APC. These findings agree with previous studies on the role of Ang II in cardioprotection by PKC-dependent, ROS-mediated p38 MAPK activation. 10, 29 However, its role in cardioprotection is still controversial. 8, 44 GSK-3β is a kinase that is phosphorylated and inhibited during preconditioning. This action has been linked to mPTP inhibition and cardioprotection. 59 GSK-3β appears to reside in the cytosol because its inhibition in isolated mitochondria has no effect on mPTP opening. 60 We did not find significant changes in the mitochondrial protein level of GSK-3β by the preconditioning protocols.
In addition to the mechanisms mentioned above, cardioprotective effects of APC can be mediated through the mitochondrial angiotensin system. Abundant and functional Ang II type 2 receptors (AT2-R) colocalised with endogenous Ang II, were found in mitochondria of mouse kidney tubular cells. Stimulation of mitochondrial AT2-Rs increased nitric oxide production and modulated the respiratory function of mitochondria. 61 Likewise, our group has reported the expression of Ang II receptors, predominantly, AT2-Rs in mitochondria of healthy rats. 62 Therefore, these findings support the idea that the mitochondrial angiotensin system could also play a role in APC.
Some limitations must be considered in the analysis of the current work. In this study, we used chelerythrine, a pan-PKC inhibitor that limits the evaluation of isoform-specific PKC-signalling in cardioprotection. We also measured total protein levels of PKCɛ, Erk1/2, Akt, PKCδ, JNK, p38 MAPK and GSK-3β in mitochondrial fractions at the end of reperfusion, to assess whether the translocation of these kinases was associated with the preconditioning protocols.
The strong pattern of change in total kinase levels observed here, and the inhibitory effect of chelerythrine on PKCɛ, Erk1/2, Akt, and JNK, but not PKCδ and GSK-3β, support their activation and translocation to the mitochondria. However, other studies failed to
show changes in total protein levels by IPC. Indeed, phospho-Akt and phospho-Erk1/2, but not total protein levels of these kinases have been reported to be increased by IPC. 35 The reason for these apparent controversies is unknown, but it is possible that the use of homogenates 35 versus the mitochondrial fractions in this study contributes to the differences observed. Indeed, Churchill et al 
| METHODS
Male Sprague-Dawley rats weighing 140-160 g were purchased from
Charles River (Wilmington, MA, USA 
| Langendorff-mode perfusion
Hearts were isolated and perfused in the Langendorff mode as described previously. 
| Animals groups
All hearts were equilibrated to the perfusion condition for 20 min- 
| Isolation of mitochondria
At the end of reperfusion, mitochondria were isolated as described previously. 7 Briefly, the ventricles were cut, weighed, and homogenized with a Polytron homogenizer in 3 mL of ice-cold sucrose buffer containing 300 mmol/L sucrose, 10 mmol/L Tris-HCl, and 2 mmol/L EGTA; pH 7.4. Mitochondria were isolated from homogenate by centrifugation at 2000 g for 3 minutes, followed by centrifugation of the supernatant at 10 000 g for 6 minutes. The pellet was then resuspended and washed two times by centrifugation at 10 000 g for 6 minutes. The final pellet containing mitochondria was resuspended and used for determination of mPTP opening and analysis of protein expression.
| Determination of mPTP opening
Swelling of de-energized mitochondria as an indicator of mPTP opening in the presence and absence of Ca 2+ was determined by monitoring the decrease in light scattering at 520 nm as described previously. 
| Western blot analysis
Immunoblotting was performed as described previously. (1:1000), GSK-3β (1:1000), and VDAC (1:1000) (Cell Signaling 
| Statistical analysis
Data are presented as mean ± SEM of 5-14 experiments per group.
Statistical differences between groups were analyzed using 2-tailed unpaired Student's t test. Cardiac function data were compared using ANOVA followed by Tukey-Kramer post-hoc tests. Differences were considered significant when P ≤ .05.
